Endo International (NASDAQ:ENDP) (TSE:ENL) issued an update on its FY18 earnings guidance on Thursday morning. The company provided EPS guidance of $2.65-2.75 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.60. The company issued revenue guidance of $2.87-2.92 billion, compared to the consensus revenue estimate of $2.81 billion.Endo International also updated its FY 2018 guidance to $2.65-2.75 EPS.
Shares of NASDAQ:ENDP opened at $13.49 on Friday. The stock has a market cap of $3.59 billion, a P/E ratio of 3.51, a PEG ratio of 1.54 and a beta of 0.65. Endo International has a 12 month low of $5.27 and a 12 month high of $18.50.
Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its quarterly earnings results on Thursday, November 8th. The company reported $0.71 EPS for the quarter, beating the consensus estimate of $0.59 by $0.12. The company had revenue of $745.00 million for the quarter, compared to the consensus estimate of $694.93 million. Endo International had a negative net margin of 34.72% and a positive return on equity of 237.45%. The firm’s revenue was down 5.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.91 EPS. On average, equities analysts predict that Endo International will post 2.68 earnings per share for the current fiscal year.
In other Endo International news, Director Roger H. Kimmel sold 26,074 shares of the business’s stock in a transaction dated Tuesday, August 14th. The shares were sold at an average price of $15.90, for a total value of $414,576.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.80% of the stock is owned by insiders.
About Endo International
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Read More: Why is Cost of Capital Important?
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.